Despite receiving many reports from consumers about Elmiron vision loss, Janssen Pharmaceuticals, Inc. and Johnson & Johnson continued marketing the prescription drug to people suffering from interstitial cystitis and bladder pain, providing them with no warnings or notice about the dangers posed by the medication. Even after multiple scientific papers have been published in medical literature and making changes to labeling in other countries, warning users of the potential for injury, the companies made no such changes in the United States.
As a result, countless patients have suffered irreparable Elmiron vision loss in the form of atypical maculopathy. This month a South Carolina woman filed a personal injury action against both Janssen Pharmaceuticals and Johnson & Johnson seeking compensation for the damage done to her by what she has called a dangerously defective prescription drug. It is expected that there will be many more such lawsuits filed in the days to come.
Elmiron Vision Loss Blamed on Failure to Provide Adequate Warnings to Patients and the Medical Community
The Elmiron vision loss claim filed against the pharmaceutical giants accuses them of designing, marketing and distributing Elmiron while knowing of the significant risks that it posed and failing to disclose it to the medical and healthcare community, Food and Drug Administration, the plaintiff herself and the public in general. They are also accused of failing to provide adequate warnings about the risks associated with the drug’s use and with withholding material adverse events from all interested parties.
The Elmiron vision loss suffered by the South Carolina woman came after over a decade of use of the medication. The claim details her having been prescribed the medication in 2001 after being diagnosed with painful bladder and/or interstitial cystitis, and beginning to experience visual symptoms in approximately 2017. In April of 2019, she was diagnosed with permanent retinal injury and vision loss which was attributed to her long-term use of the medication. She has indicated that had she known of the risk she would not have taken the medication, and her physicians likewise maintain that they would not have prescribed the medication, or at the very least would have actively monitored her vision to prevent the outcome that she has experienced.